Xiaoqing Wu

7PUBLICATIONS
32CO-AUTHORS
Rehabilitation engineeringRespiratory diseasesMolecular targetsCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markers
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (7)

|May 29, 2026
Pharmacologic disruption of HuR-RNA interactions prevents maladaptive tubular repair and AKI-to-CKD progression.

|Mar 14, 2025
HuR inhibition reduces post-ischemic cardiac remodeling by dampening myocyte-dependent inflammatory gene expression and the innate immune response.

Samuel Slone, Sarah R Anthony, Lisa C Green

|Dec 20, 2024
HuR inhibition overcomes cFLIP-mediated doxorubicin resistance in triple-negative breast cancer.

Lanjing Wei, Sung Hae Kim, Ahlam M Armaly

|Dec 03, 2024
RNA-binding protein HuR inhibition induces multiple programmed cell death in breast and prostate cancer.

Lanjing Wei, Sung Hae Kim, Ahlam M Armaly

|Jun 26, 2023
Functional inhibition of the RNA-binding protein HuR sensitizes triple-negative breast cancer to chemotherapy.

Lanjing Wei, Qi Zhang, Cuncong Zhong

|Jun 12, 2020
Molecular and functional extracellular vesicle analysis using nanopatterned microchips monitors tumor progression and metastasis.

Peng Zhang, Xiaoqing Wu, Gulhumay Gardashova

Pageof 2

Frequent Collaborators

5 joint publications

Liang Xu

3 joint publications

Jeffrey Aubé

2 joint publications

Gulhumay Gardashova

2 joint publications

Sudeshna Roy